PhaseBio Pharmaceuticals Inc. (PHAS) and argenx SE (NASDAQ:ARGX) Comparing side by side

We will be contrasting the differences between PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and argenx SE (NASDAQ:ARGX) as far as risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PhaseBio Pharmaceuticals Inc. 9 168.16 N/A 4.52 1.73
argenx SE 129 0.00 N/A -1.73 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for PhaseBio Pharmaceuticals Inc. and argenx SE.

Profitability

Table 2 has PhaseBio Pharmaceuticals Inc. and argenx SE’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
PhaseBio Pharmaceuticals Inc. 0.00% 0% 0%
argenx SE 0.00% 0% 0%

Analyst Recommendations

In next table is delivered PhaseBio Pharmaceuticals Inc. and argenx SE’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PhaseBio Pharmaceuticals Inc. 0 0 0 0.00
argenx SE 0 0 3 3.00

Competitively the average price target of argenx SE is $166.67, which is potential 18.89% upside.

Insider & Institutional Ownership

The shares of both PhaseBio Pharmaceuticals Inc. and argenx SE are owned by institutional investors at 57.7% and 55.81% respectively. 0.4% are PhaseBio Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PhaseBio Pharmaceuticals Inc. -16.74% -43.73% -40.97% 120% 0% 152.75%
argenx SE -1.84% -1.67% 13.7% 35.71% 53.91% 46.21%

For the past year PhaseBio Pharmaceuticals Inc. was more bullish than argenx SE.

Summary

PhaseBio Pharmaceuticals Inc. beats argenx SE on 5 of the 7 factors.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.